Gene Expression Profiling Predicts PARP Inhibitor Response in Malignant Pleural Mesothelioma

Study Background and Research Question

Malignant pleural mesothelioma (MPM) remains a highly aggressive cancer, largely resistant to conventional therapies and associated with a poor median survival. Current standard-of-care for unresectable or advanced MPM involves combination chemotherapy with pemetrexed disodium and cisplatin, yet response rates hover around 40%, and relapse is common. This therapeutic inertia highlights a pressing need to dissect the biological mechanisms underlying chemoresistance in MPM and to identify patient subgroups who might benefit from targeted approaches. Borchert et al. (2019) set out to investigate whether gene expression profiling of the homologous recombination repair (HRR) pathway could serve as a predictor for response to PARP inhibition, specifically with olaparib, in MPM cell lines and clinical samples.

Key Innovation from the Reference Study

The principal innovation of the Borchert et al. study lies in leveraging the concept of "BRCAness"—a phenotype defined by defects in the HRR pathway, akin to BRCA1/2 mutations—to stratify MPM tumors. By examining gene expression patterns linked to HRR dysfunction, the authors demonstrated that a subset of MPM tumors exhibit molecular features that could sensitize them to synthetic lethality induced by PARP inhibitors. Importantly, they correlated BAP1 loss-of-function (a frequent event in MPM) with increased apoptosis and senescence in response to olaparib, particularly when combined with cisplatin, suggesting a new rationale for combination therapy in this setting.

Methods and Experimental Design Insights

The study utilized a dual approach: in vitro cytotoxicity assays and clinical gene expression analysis. Three MPM cell lines, along with normal lung fibroblasts as controls, were exposed to pemetrexed, cisplatin, and olaparib, both as monotherapies and in combination. Apoptosis and senescence endpoints were measured to assess treatment effects. In parallel, 91 clinical MPM samples were digitally screened for the expression of 91 genes implicated in HRR, focusing on those grouped under the BRCAness phenotype (including BAP1, AURKA, RAD50, and DDB2).

Response to treatment was stratified by the mutational and transcriptional status of these genes, enabling the authors to correlate specific HRR defects with experimental outcomes. This design provided both mechanistic insight and translational relevance, linking laboratory findings to potential patient stratification strategies.

Core Findings and Why They Matter

Key findings from Borchert et al. (2019) include:

• MPM cell lines characterized by BAP1 mutation—a marker of BRCAness—exhibited increased apoptosis and senescence following olaparib treatment, particularly in combination with cisplatin.
• Approximately 10% of the clinical MPM samples displayed gene expression patterns consistent with BRCAness, suggesting a significant subset of patients may be amenable to PARP inhibitor-based strategies.
• Gene expression levels of AURKA, RAD50, and DDB2 were identified as prognostic markers, providing potential biomarkers for patient stratification.
• The findings support the hypothesis that DNA repair pathway defects, beyond classical BRCA1/2 mutations, can confer sensitivity to PARP inhibition in MPM, thus expanding the therapeutic window for these agents.

This work advances the understanding of chemoresistance in MPM and proposes a rational framework for integrating HRR profiling into research and clinical decision-making. It underscores the importance of functional genomics in identifying actionable vulnerabilities within tumors otherwise considered refractory to existing regimens.

Comparison with Existing Internal Articles

Several recent internal reviews have explored the mechanistic and translational implications of targeting DNA repair deficiencies and folate metabolism in cancer chemotherapy research. For instance, "Pemetrexed as a Precision Probe" discusses how multi-targeted antifolates like pemetrexed can be leveraged to disrupt nucleotide biosynthesis and sensitize tumor models—particularly those with HRR defects—to DNA damaging agents and combination therapies. This aligns with Borchert et al.'s emphasis on exploiting DNA repair vulnerabilities in MPM.

Another article, "Pemetrexed in Translational Oncology", provides a roadmap for integrating gene expression profiling and antifolate treatment strategies to overcome chemoresistance in tumors such as non-small cell lung carcinoma and mesothelioma. Both internal resources highlight how systematic characterization of DNA repair pathways informs the rational use of agents like pemetrexed and fosters the development of synergistic combinations—including those involving PARP inhibitors, as described in the reference study.

Limitations and Transferability

While the findings of Borchert et al. are promising, several limitations should be noted. First, the proportion of MPM cases exhibiting BRCAness-like gene expression is relatively modest (~10%), which may constrain the broad applicability of PARP inhibitor strategies. Secondly, the study's in vitro models, although informative, may not fully recapitulate the complexity of tumor microenvironments and drug resistance observed in vivo. Further, while the link between BAP1 loss and PARP inhibitor sensitivity is compelling, prospective validation in clinical trials will be essential to confirm translational impact.

The transferability of these results to other cancer types or therapeutic settings should also be approached with caution. The molecular landscape of DNA repair defects is heterogeneous, and context-dependent factors may influence response to both pemetrexed and PARP inhibitors.

Protocol Parameters

• Gene expression profiling: Digital screening of 91 HRR-related genes in 91 MPM clinical samples, focusing on BRCAness markers (e.g., BAP1, AURKA, RAD50, DDB2).
• In vitro drug exposure: MPM cell lines treated with pemetrexed, cisplatin, and olaparib as monotherapies and in combination; apoptosis and senescence measured as endpoints.
• Patient stratification: Grouping based on presence/absence of BRCAness gene expression patterns for potential prediction of PARP inhibitor response.
• Antiproliferative agent testing: Literature suggests pemetrexed is effective in vitro at concentrations from 0.0001 to 30 μM over 72 hours, as supported by product information.

Research Support Resources

Researchers aiming to replicate or extend studies involving DNA repair profiling and chemotherapy sensitivity in MPM can utilize Pemetrexed (SKU A4390) as a validated antifolate antimetabolite for mechanistic and translational assays. APExBIO’s pemetrexed is frequently employed in cancer chemotherapy research for its multi-targeted inhibition of nucleotide biosynthesis and robust antiproliferative effects in tumor cell lines. For additional methodological context, see this article on practical assay design in cancer cell models.